The FDA Wants to Bar Big Compounders From Tirzepatide. Here's What It Means for Your Compounded Tirzepatide.
An FDA proposal would permanently pull semaglutide, tirzepatide, and liraglutide off the list of bulk ingredients that large outsourcing facilities are allowed to compound — and the public comment window closed June 29. Before you panic-refill or panic-quit, here's what's actually on the table, what stays legal, and what I'd do while the agency weighs its decision.
If you take compounded tirzepatide, you have probably had three different people send you the same screenshot, each with a slightly more alarming caption. So let me do the thing I started this site to do: read the actual FDA document, translate it out of regulator-speak, and tell you what it does and doesn't change for the vial in your refrigerator.
On April 30, 2026, the FDA announced a proposal to exclude semaglutide, tirzepatide, and liraglutide from what's called the 503B bulks list, per the agency's own announcement. The agency said it “did not identify a clinical need” for outsourcing facilities to make these drugs from bulk ingredients. It's a proposal, not a final rule — and the FDA took public comments through June 29, 2026 before deciding. (Update: that comment window has now closed. The FDA is reviewing what it received and has not issued a final determination as of this update — so nothing has actually changed for patients yet.) The deadline is the part most of the scary captions left out.
What is the 503B bulks list, in mom English?
There are two kinds of compounding pharmacies, and the difference is the whole story here.
- 503A pharmacies make a medication for one specific patient, with a prescription, the way a corner compounding pharmacy always has.
- 503B outsourcing facilities are the big operations that compound in large batches from bulk powder — the volume engine behind a lot of the cheap, mass-marketed online GLP-1 you've seen advertised.
The 503B bulks list is the FDA's roster of bulk ingredients those big facilities are allowed to use. Take tirzepatide off that list, and the large-scale, bulk-batch version of compounded tirzepatide loses its legal footing at the outsourcing-facility level. That's what this proposal aims to do. Mom translation: the FDA is going after the firehose, not the prescription your provider writes for you by name.
So is compounded tirzepatide about to be illegal?
No — and anyone telling you to prepay a year's supply “before the ban” is reading you, not the rule. Two things keep that from being true.
First, this is a proposal the FDA is still working through — the comment window closing on June 29 was a deadline for feedback, not a switch that flipped anything off. Second, and more important for you: the individual-patient pathway is a different lane. A licensed 503A pharmacy can still prepare tirzepatide for a specific patient with a documented clinical reason — an allergy to an inactive ingredient in the brand product, or a personalized formulation or strength that isn't commercially available. That's the same framework our resources page has described since this year's earlier FDA updates: compounded tirzepatide is legal when it's made for you, by a licensed pharmacy, for a real medical reason — not dispensed in bulk purely because it's cheaper. This proposal tightens the bulk lane; it doesn't close the patient-specific one.
What it almost certainly does mean: the rock-bottom, no-evaluation, buy-six-months-in-one-click model gets harder to operate legally. If your “provider” is really just a storefront in front of a bulk outsourcing facility, this is the proposal that squeezes them. If your provider is a real clinician writing a real prescription to a named, licensed pharmacy, you are on much steadier ground.
One thing to keep straight: compounded was never FDA-approved
This is the moment to repeat the unglamorous fact this whole site is built on: compounded tirzepatide is not FDA-approved, and never has been. The brand-name versions went through the approval process; compounded versions are prepared by licensed pharmacies under a separate, narrower set of rules. None of that is new, and none of it makes compounded medication automatically unsafe — it makes where you get it the entire ballgame. A proposal that narrows who can legally make it at scale is, if anything, the FDA underlining that point for you.
Why this is exactly when the scam risk spikes
Here's the part that turns my stomach a little. Every time a headline says “FDA” and “crackdown” in the same sentence, the fake-pharmacy crowd has its best month. People get scared, supply feels uncertain, and a slick website promising to “lock in your price before the ban” starts to look like a lifeline instead of a trap. The FDA has warned that some fraudulent online sellers label their products with the names of real licensed pharmacies that never touched the vial, per the FDA's consumer page on unapproved GLP-1 drugs. A regulatory shake-up is chum in the water for exactly that move. I wrote a whole field guide to how these scams actually work if you want the four shapes they take.
So the rule for the next few weeks is the same rule as always, just louder: a real medical intake before any money changes hands, a pharmacy you can name and verify with the state board, and absolutely no countdown-timer urgency. My full provider checklist is built for precisely this kind of moment.
Don't panic-buy. Verify, then breathe.
The FDA's proposal targets large-scale bulk compounding by outsourcing facilities — not the patient-specific prescription a real provider writes for you. The comment window has closed, and nothing is final until the FDA issues its determination. If you use compounded tirzepatide, this is a good week to confirm your provider is a licensed clinician working with a named, verifiable pharmacy — and a terrible week to wire a year's payment to a website you can't look up.
What I'd do this week
- Don't stockpile in a panic. A “beat the ban” bulk order is the exact behavior bad actors are counting on. There was no ban on June 29 — there was a comment deadline, and the FDA is still deciding.
- Name your pharmacy. Ask your provider which licensed compounding pharmacy fills your prescription, and confirm it's a real 503A pharmacy serving you as an individual patient. If they can't or won't tell you, that's your answer.
- Talk to your actual provider, not a comment section. If you're worried about continuity, ask your licensed prescriber what their plan is. That's a medical conversation, and it's theirs to have with you — not mine, and definitely not a stranger's on social media.
- Run anyone new through the checklist. If this nudges you to shop around, do it with the five-point checklist open. The eighteen-months-in-business filter alone screens out most of the operators a crackdown is about to wash away.
Regulations like this one are genuinely worth watching, and I'll keep doing that here. But the thing that protects you isn't predicting what the FDA finalizes in the coming months. It's the same boring discipline it's always been: knowing exactly who made your medication, and refusing to hand your card to anyone who won't tell you.
Sources & further reading
- FDA: “FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List” — the primary announcement, reasoning, and the June 29, 2026 comment deadline
- STAT News: FDA wants to exclude weight-loss drugs from a compounding list — reporting on the proposal and what it means for consumers
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss — including fraudulent products labeled with the names of pharmacies that never made them
- Related: how tirzepatide online scams actually work, and my provider checklist
Medical disclaimer: The Compounded Brief is not a pharmacy, prescriber, or medical provider, and nothing here is medical advice. Compounded medications are not FDA-approved; obtain them only from a licensed compounding pharmacy after evaluation by a licensed provider. Regulations and availability are changing quickly; confirm current details with the FDA and your own licensed provider. Talk to a licensed professional before starting, stopping, or changing any medication.